Get the Stockscreener App
18.23
4.17%
0.73
After Hours:
18.23
Monte Rosa Therapeutics Inc stock is traded at $18.23, with a volume of 944.19K.
It is up +4.17% in the last 24 hours and up +13.80% over the past month.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
See More
Previous Close:
$17.50
Open:
$17.53
24h Volume:
944.19K
Relative Volume:
0.78
Market Cap:
$1.46B
Revenue:
$123.67M
Net Income/Loss:
$-38.63M
P/E Ratio:
-29.55
EPS:
-0.617
Net Cash Flow:
$-27.50M
1W Performance:
+6.48%
1M Performance:
+13.80%
6M Performance:
+64.09%
1Y Performance:
+311.51%
1-Day Range:
$17.35
$18.50
1-Week Range:
$16.89
$18.50
52-Week Range:
$3.51
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
18.23 | 1.40B | 123.67M | -38.63M | -27.50M | -0.617 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Warmuth, Monte Rosa Therapeutics CEO, sells $141k in Glue stock - Investing.com Australia
Markus Warmuth sells 5,466 shares of GLUE (NASDAQ: GLUE) under Rule 144 - Stock Titan
Edmund Dunn files Form 144 reporting GLUE (NASDAQ: GLUE) common stock sales - Stock Titan
Insider Sell: Philip Nickson Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus
Monte Rosa Therapeutics Insider Sells Over $100K in Shares - National Today
Philip Nickson Sells 5,845 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock - MarketBeat
Insider at Monte Rosa Therapeutics (GLUE) sells 5,845 shares - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
26,117 GLUE shares reported for sale (NASDAQ: GLUE) in Form 144 - Stock Titan
GLUE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Performance Recap: Is Monte Rosa Therapeutics Inc forming a bullish divergenceCEO Change & Detailed Earnings Play Strategies - baoquankhu1.vn
Aug Momentum: Is Monte Rosa Therapeutics Inc subject to activist investor interest2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE) grants equity awards to accounting chief - Stock Titan
Monte Rosa Therapeutics (NASDAQ: GLUE) officer reports stock and option holdings in Form 3 - Stock Titan
Investor Mood: How sensitive is Monte Rosa Therapeutics Inc to inflationTrend Reversal & Proven Capital Preservation Tips - baoquankhu1.vn
Analysts’ Top Healthcare Picks: Nurix Therapeutics (NRIX), Immunocore Holdings (IMCR) - The Globe and Mail
Quarterly Earnings: How sensitive is Monte Rosa Therapeutics Inc to inflation2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn
Gainers Report: What are the risks of holding Monte Rosa Therapeutics IncRisk Management & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aug Patterns: Can Monte Rosa Therapeutics Inc lead its sector in growth2026 Technicals & Weekly Momentum Picks - baoquankhu1.vn
Does J&J-Backed MRT-2359 Prostate Cancer Trial Change The Bull Case For Monte Rosa Therapeutics (GLUE)? - simplywall.st
Trading Recap: Will Monte Rosa Therapeutics Inc benefit from AI trends2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Johnson & Johnson MRT-2359 Trial Supply Agreement - Sahm
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Therapeutics urges new pathways for the next generation of scientists - Traders Union
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Aug Ideas: Can Monte Rosa Therapeutics Inc lead its sector in growthQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Can Monte Rosa Therapeutics Inc lead its sector in growthTrade Ideas & Long-Term Capital Growth Ideas - baoquankhu1.vn
Breakouts Watch: How sensitive is Monte Rosa Therapeutics Inc to inflationQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Big Picture: Does Monte Rosa Therapeutics Inc stock have upside surprise potentialRate Hike & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story - Yahoo Finance
Wall Street Zen Downgrades Monte Rosa Therapeutics to 'Sell' - National Today
Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Risks Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceQuarterly Earnings Summary & Verified Technical Signals - baoquankhu1.vn
Does Monte Rosa Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Lantheus (LNTH) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00 - MarketBeat
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim - TipRanks
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative - simplywall.st
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses - AlphaStreet
Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Monte Rosa Therapeutics Reports Positive Clinical Data and $345M Financing, Advancing Multiple Phase 2 Trials into 2029 - Minichart
Is Monte Rosa Therapeutics Inc stock a hidden gem2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Monte Rosa Therapeutics (GLUE) reports Q4 loss, misses revenue estimates - MSN
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% - AlphaStreet
Monte Rosa’s QuEEN™ Discovery Engine: AI-Driven Molecular Glue Degraders Targeting Undruggable Proteins in Biotechnology 4145465158 - Minichart
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):